The diagnosis is the product.

Every firm sells the intervention. The rebrand. The outbound engine. The pricing revamp. The sales enablement stack. The buyer, who has been sold interventions before, knows the pattern: six weeks of workshops, a deliverable, a Slack channel that goes quiet, a modest lift attributed to seasonality. The intervention is legible; the intervention is safe; the intervention is not, mostly, what the company needed.

What the company needed was a diagnosis — a document that describes what is actually broken, in the operator's own vocabulary, with the evidence on the page. Diagnoses are unfashionable to sell because they cannot be dressed up as urgency. They cannot be A/B tested. They do not fit inside a QBR. A diagnosis, done well, is thirty to sixty pages long, is read once by the CEO in a single sitting, and changes the shape of the next four quarters.

The reason diagnoses are rare is that they are difficult, boring to produce, and legible only to a buyer who has already learned to distrust interventions. The firms that lead with diagnosis are self-selecting for a smaller market — operators who have run at least one cycle of the intervention theater and are not looking to run another.

The diagnosis is the product. Everything downstream — the design, the build, the run — is delivery. A firm that will not write down what is wrong before it starts building is not a firm; it is a supplier. In 2026, with three vendors ready to sell the same intervention the next Tuesday, the differentiator is the sentence at the top of the diagnosis: this is what is broken, and here is the evidence.